844 related articles for article (PubMed ID: 32003657)
1. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p/PD-L1 axis.
Ling J; Sun Q; Tian Q; Shi H; Yang H; Ren J
Arch Biochem Biophys; 2022 Nov; 731():109449. PubMed ID: 36288761
[TBL] [Abstract][Full Text] [Related]
5. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
6. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
7. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
Cai H; Yan L; Liu N; Xu M; Cai H
Biomed Pharmacother; 2020 Mar; 123():109790. PubMed ID: 31896065
[TBL] [Abstract][Full Text] [Related]
8. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
9. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
Chen W; Zhang Y; Zhao C; Shao S; Zhang Y; Li X; Bai X; Guo Q; Liu Q; Tang J; Zhang L
Front Immunol; 2020; 11():612547. PubMed ID: 33552075
[TBL] [Abstract][Full Text] [Related]
10. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
11. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Ottenhof SR; Djajadiningrat RS; de Jong J; Thygesen HH; Horenblas S; Jordanova ES
J Urol; 2017 Mar; 197(3 Pt 1):690-697. PubMed ID: 27697578
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
13. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer.
Aghbash PS; Hemmat N; Baradaran B; Mokhtarzadeh A; Poortahmasebi V; Oskuee MA; Baghi HB
Oncol Res; 2022; 30(3):99-116. PubMed ID: 37305016
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide Profiling of Human Papillomavirus DNA Integration into Human Genome and Its Influence on PD-L1 Expression in Chinese Uygur Cervical Cancer Women.
Yang-Chun F; Sen-Yu W; Yuan Z; Yan-Chun H
J Immunol Res; 2020; 2020():6284960. PubMed ID: 32411801
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Vaginal Microecology, Serum miR-18a, and PD-L1 for Identifying HPV-Positive Cervical Cancer.
Zhang Y; Qiu S; Guo Y; Zhang J; Wu X; Hong G
Technol Cancer Res Treat; 2021; 20():1533033821995281. PubMed ID: 33632085
[TBL] [Abstract][Full Text] [Related]
16. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
17. CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts
Chen X; He H; Xiao Y; Hasim A; Yuan J; Ye M; Li X; Hao Y; Guo X
Front Oncol; 2021; 11():629350. PubMed ID: 34422627
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.
Wang Y; Li G
Front Med; 2019 Aug; 13(4):438-450. PubMed ID: 30826965
[TBL] [Abstract][Full Text] [Related]
19. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Patel JJ; Levy DA; Nguyen SA; Knochelmann HM; Day TA
Head Neck; 2020 Apr; 42(4):774-786. PubMed ID: 31762164
[TBL] [Abstract][Full Text] [Related]
20. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
